Virtu Financial LLC bought a new position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 16,444 shares of the company’s stock, valued at approximately $862,000.
Other institutional investors have also recently made changes to their positions in the company. Mcguire Capital Advisors Inc. acquired a new stake in shares of CRISPR Therapeutics in the fourth quarter valued at about $25,000. Axxcess Wealth Management LLC lifted its stake in shares of CRISPR Therapeutics by 6.2% in the fourth quarter. Axxcess Wealth Management LLC now owns 13,022 shares of the company’s stock worth $683,000 after acquiring an additional 764 shares during the period. Corient Private Wealth LLC lifted its stake in shares of CRISPR Therapeutics by 5.7% in the fourth quarter. Corient Private Wealth LLC now owns 8,566 shares of the company’s stock worth $449,000 after acquiring an additional 460 shares during the period. Jacobs Equity LLC bought a new stake in CRISPR Therapeutics in the fourth quarter valued at approximately $634,000. Finally, Empowered Funds LLC bought a new stake in CRISPR Therapeutics in the fourth quarter valued at approximately $165,000. Institutional investors own 69.20% of the company’s stock.
Insider Activity at CRISPR Therapeutics
In other news, insider Naimish Patel sold 3,786 shares of CRISPR Therapeutics stock in a transaction on Friday, May 29th. The shares were sold at an average price of $55.62, for a total value of $210,577.32. Following the completion of the sale, the insider owned 19,357 shares in the company, valued at $1,076,636.34. The trade was a 16.36% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 4.10% of the stock is currently owned by company insiders.
CRISPR Therapeutics Stock Performance
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last issued its earnings results on Tuesday, March 31st. The company reported ($1.28) earnings per share for the quarter. CRISPR Therapeutics had a negative return on equity of 25.66% and a negative net margin of 13,856.54%.The business had revenue of $1.46 million during the quarter. Research analysts expect that CRISPR Therapeutics AG will post -4.89 earnings per share for the current year.
Wall Street Analysts Forecast Growth
CRSP has been the subject of several analyst reports. Evercore restated an “outperform” rating and set a $76.00 price target on shares of CRISPR Therapeutics in a report on Monday, May 11th. Piper Sandler restated an “overweight” rating and issued a $110.00 price target (up from $105.00) on shares of CRISPR Therapeutics in a research report on Tuesday, March 17th. Morgan Stanley set a $60.00 price objective on shares of CRISPR Therapeutics and gave the company an “equal weight” rating in a research note on Thursday, June 11th. Citigroup reiterated a “market outperform” rating on shares of CRISPR Therapeutics in a research report on Wednesday, May 27th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of CRISPR Therapeutics in a research note on Monday, April 20th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, CRISPR Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $67.78.
View Our Latest Analysis on CRISPR Therapeutics
CRISPR Therapeutics Profile
CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.
Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.
Featured Articles
- Five stocks we like better than CRISPR Therapeutics
- 3 Inflation-Fighting Stocks Built for Higher Oil Prices
- 3 Biotech Firms With Major Potential Catalysts in the Coming Months
- Applied Materials Stock Looks Pricey—Can AI Demand Justify the Rally?
- 3 Small-Cap Stocks Getting a Russell 2000 Rebalance Boost
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
